This Article  • Full text  • PDF  • eAppendix  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Journalology/ Peer Review/ Authorship  • Patient Safety/ Medical Error  • Statistics and Research Methods  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Isabelle Pitrou, MD, MSc; Isabelle Boutron, MD, PhD; Nizar Ahmad, MD, MSc; Philippe Ravaud, MD, PhD

Arch Intern Med. 2009;169(19):1756-1761.

Background  Reports of clinical trials usually emphasize efficacy results, especially when results are statistically significant. Poor safety reporting can lead to misinterpretation and inadequate conclusions about the interventions assessed. Our aim was to describe the reporting of harm-related results from randomized controlled trials (RCTs).

Methods  We searched the MEDLINE database for reports of RCTs published from January 1, 2006, through January 1, 2007, in 6 general medical journals with a high impact factor. Data were extracted by use of a standardized form to appraise the presentation of safety results in text and tables.

Results  Adverse events were mentioned in 88.7% of the 133 reports. No information on severe adverse events and withdrawal of patients owing to an adverse event was given in 27.1% and 47.4% of articles, respectively. Restrictions in the reporting of harm-related data were noted in 43 articles (32.3%) with a description of the most common adverse events only (n = 17), severe adverse events only (n = 16), statistically significant events only (n = 5), and a combination of restrictions (n = 5). The population considered for safety analysis was clearly reported in 65.6% of articles.

Conclusion  Our review reveals important heterogeneity and variability in the reporting of harm-related results in publications of RCTs.

Author Affiliations: Département d’Epidémiologie, Biostatistique, et Recherche Clinique, Groupe Hospitalier Bichat-Claude Bernard (AP-HP); Université Denis Diderot; INSERM U738, Paris, France.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Adverse Events in Randomized Trials: Neglected, Restricted, Distorted, and Silenced
John P. A. Ioannidis
Arch Intern Med. 2009;169(19):1737-1739.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adverse Events in Randomized Trials: Neglected, Restricted, Distorted, and Silenced
Ioannidis
Arch Intern Med 2009;169:1737-1739.
FULL TEXT